Nerveda-backed RetroSense Therapeutics has raised money from investors including Santen Pharmaceutical, and will put the cash towards clinical studies.

The Sanofi-backed gene therapy company floated below its $15 to $17 range, but its shares have since risen to $17.50.

Biopharmaceutical company Wave Life Sciences has gone public at the middle of its range just nine months after closing its $18m SNBL-led series A round.

Merck, Amgen and EMS invested alongside a range of venture capital firms, eight months after Miragen closed its $21.5m series B round.

Sunnyhealth has joined forces with Fenox Venture Capital to invest in startups across the world to help them enter the Japanese market.

GlaxoSmithKline and Avalon Ventures have launched the seventh company under their partnership agreement.